William R. Jacobs

Dr. William R. Jacobs

Department of Microbiology & Immunology, Albert Einstein College of Medicine, Yeshiva University, New York, NY 10033, USA
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 1991 in Nature
Verified
Journal Article
Closed access
CSC. K. Stover
C. K. Stover
VCV. F. de la Cruz
V. F. de la Cruz
TFT. R. Fuerst
T. R. Fuerst
JBJ. E. Burlein
J. E. Burlein
LBL. A. Benson
L. A. Benson
BBB. R. Bloom
B. R. Bloom

17 August 2000 in Nature
Verified
Journal Article
Closed access
PDF file
JMJohn D. McKinney
John D. McKinney
KBKerstin Höner zu Bentrup
Kerstin Höner zu Bentrup
EMErnesto J. Muñoz-Elías
Ernesto J. Muñoz-Elías
AMAndras Miczak
Andras Miczak
BCBing Chen
Bing Chen
DRDavid Russell
David Russell

14 January 1994 in Science
Verified
Journal Article
Closed access
PDF file
ABAsesh Banerjee
Asesh Banerjee
EDEugenie Dubnau
Eugenie Dubnau
AQAnnaik Quemard
Annaik Quemard
VBV. Balasubramanian
V. Balasubramanian
KUKyung Sun Um
Kyung Sun Um
WJWilliam R. Jacobs
William R. Jacobs
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.

13 October 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
THTsungda Hsu
Tsungda Hsu
SHSuzanne M. Hingley-Wilson
Suzanne M. Hingley-Wilson
BCBing Chen
Bing Chen
MCMei Chen
Mei Chen
ADAnnie Z. Dai
Annie Z. Dai
WJWilliam R. Jacobs
William R. Jacobs
Tuberculosis remains a leading cause of death worldwide, despite the availability of effective chemotherapy and a vaccine. Bacillus Calmette–Guérin (BCG), the tuberculosis vaccine, is an attenuated mutant of Mycobacterium bovis that was isolated after serial subcultures, yet the functional basis for this attenuation has never been elucidated. A single region ( RD1 ), which is absent in all BCG substrains, was deleted from virulent M. bovis and Mycobacterium tuberculosis strains, and the resulting Δ RD1 mutants were significantly attenuated for virulence in both immunocompromised and immunocompetent mice. The M. tuberculosis Δ RD1 mutants were also shown to protect mice against aerosol challenge, in a similar manner to BCG. Interestingly, the Δ RD1 mutants failed to cause cytolysis of pneumocytes, a phenotype that had been previously used to distinguish virulent M. tuberculosis from BCG. A specific transposon mutation, which disrupts the Rv3874 Rv3875 ( cfp-10 esat-6 ) operon of RD1 , also caused loss of the cytolytic phenotype in both pneumocytes and macrophages. This mutation resulted in the attenuation of virulence in mice, as the result of reduced tissue invasiveness. Moreover, specific deletion of each transcriptional unit of RD1 revealed that three independent transcriptional units are required for virulence, two of which are involved in the secretion of ESAT-6 (6-kDa early secretory antigenic target). We conclude that the primary attenuating mechanism of bacillus Calmette–Guérin is the loss of cytolytic activity mediated by secreted ESAT-6, which results in reduced tissue invasiveness.

23 January 1992 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CDCharles L. Daley
Charles L. Daley
PSPeter M. Small
Peter M. Small
GSGisela F. Schecter
Gisela F. Schecter
GSGary K. Schoolnik
Gary K. Schoolnik
RMRuth A. McAdam
Ruth A. McAdam
PHPhilip C. Hopewell
Philip C. Hopewell
Tuberculosis typically develops from a reactivation of latent infection. Clinical tuberculosis may also arise from a primary infection, and this is thought to be more likely in persons infected with the human immunodeficiency virus (HIV). However, the relative importance of these two pathogenetic mechanisms in this population is unclear.

4 November 1999 in Nature
Verified
Journal Article
Closed access
PDF file
JCJeffery S. Cox
Jeffery S. Cox
BCBing Chen
Bing Chen
MMMichael McNeil
Michael McNeil
WJWilliam R. Jacobs
William R. Jacobs